ReviewJournal of neurogastroenterology and motility2017
Biomarkers of Irritable Bowel Syndrome.
Review in Journal of neurogastroenterology and motility, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of biophenol-rich nutraceuticals in adults with inflammatory gastrointestinal diseases or irritable bowel syndrome: A systematic literature review and meta-analysis.Nutrition & dietetics : the journal of the Dietitians Association of Australia · 2022Pooled it
- Biofeedback for treatment of irritable bowel syndrome.The Cochrane database of systematic reviews · 2019Pooled it
- Long-Term Effects of a Web-Based Low-FODMAP Diet Versus Probiotic Treatment for Irritable Bowel Syndrome, Including Shotgun Analyses of Microbiota: Randomized, Double-Crossover Clinical Trial.Journal of medical Internet research · 2021Trial
- Trial
- Biomarkers in Irritable Bowel Syndrome: Bridging Gut-Brain Mechanisms to Precision Care.Current gastroenterology reports · 2026Review
- Biomarkers and immunomodulatory effect of erythropoietin in postoperative ileus.BMC research notes · 2026Article
- Development and validation of a machine learning scoring system based on multi-dimensional metabolic signatures for invasive examination triage in intestinal diseases.Frontiers in genetics · 2026Article
- Serum FGL2 is correlated with the severity and psychological status of diarrhea-predominant irritable bowel syndrome.Frontiers in medicine · 2026Article
- Pathophysiological Mechanisms and Nonpharmacological Interventions in Irritable Bowel Syndrome: Current Insights and Future Directions.Journal of nutrition and metabolism · 2026Review
- Development and Validation of a Multimodal Wearable Belt for Abdominal Biosignal Monitoring with Application to Irritable Bowel Syndrome.Micromachines · 2025Article
- Precision Medicine in Disorders of Gut-Brain Interaction.Gastroenterology & hepatology · 2025Article
- Intestinal biomarkers, microbiota composition, and genetic predisposition to inflammatory bowel disease as predictors of Parkinson's disease manifestation.Journal of Parkinson's disease · 2025Article
- Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients.BMC gastroenterology · 2024Article
- New Role of the Serotonin as a Biomarker of Gut-Brain Interaction.Life (Basel, Switzerland) · 2024Review
- The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome.Journal of clinical medicine · 2024Review
- The pan-microbiome profiling system Taxa4Meta identifies clinical dysbiotic features and classifies diarrheal disease.The Journal of clinical investigation · 2024Article
- Low-level inflammation, immunity, and brain-gut axis in IBS: unraveling the complex relationships.Gut microbes · 2023Review
- Gut Dysbiosis in Irritable Bowel Syndrome: A Narrative Review on Correlation with Disease Subtypes and Novel Therapeutic Implications.Microorganisms · 2023Review
- Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome-wide association study.United European gastroenterology journal · 2023Article
- Functional Implications and Clinical Potential of MicroRNAs in Irritable Bowel Syndrome: A Concise Review.Digestive diseases and sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditionally, irritable bowel syndrome (IBS) has not been regarded as an organic disease, and the pathophysiology of IBS is heterogeneous. Currently, the diagnosis of IBS is based upon the Rome diagnostic criteria. The performance of these criteria is only modest in predicting IBS, and moreover their validation is lacking. Additionally, as functional symptoms are common in the general population, healthy controls or volunteers are difficult to define and there is currently no definition of "normal" in the Rome criteria. Due to the weaknesses of the current diagnostic criteria, patients and doctors expect new gold standard diagnostic tools. Various etiologic mechanisms result in potential biomarkers. The focus of this research has been to find non-invasive biomarkers from serum, breath gas, and fecal materials. Though biomarkers should be based on biological and pathogenic processes, most biomarkers for IBS have been developed to identify organic diseases and therefore eliminate IBS. To date, these types of biomarkers for IBS have been disappointing. The purposes of developing biomarkers include improvement of diagnosis, differentiation from other organic diseases, and discrimination of IBS subtypes. A true mechanistic biomarker would make it possible to rule in IBS, rather than to rule out other organic diseases. New serologic biomarkers for diarrhea-predominant IBS have been introduced based on the pathophysiologic findings from a rat model and validation in a large-scale clinical trial. Further investigations of abnormal organic findings from each subtype of IBS would enable the development of new, simple subtype-specific biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.